Illumina and Tempus join forces to expand genomic testing

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) today announced a partnership aimed at advancing the use of artificial intelligence (AI) in genomic sequencing to enhance patient care in precision medicine. The collaboration seeks to generate evidence supporting the clinical benefits of molecular profiling, with the goal of making such testing a standard component of care across all major disease categories. With annual revenue of $4.37 billion and a robust gross margin of 68%, Illumina brings significant operational scale to this partnership. According to InvestingPro data, analysts expect the company’s net income to grow this year, suggesting strong potential for this strategic initiative.

The initiative will utilize Illumina’s AI technologies and Tempus’s extensive multimodal data platform to develop genomic algorithms. These efforts are expected to improve patient outcomes by enabling more precise therapy selection based on individual molecular profiles, not only in oncology but also in other fields such as cardiology and neurology.

Everett Cunningham, Illumina’s chief commercial officer, emphasized the importance of molecular insights in directing patients to the most effective treatments. Tempus’s chief commercial officer, Terron Bruner, also highlighted the combined technological and analytical strengths of both companies as a driving force for innovation in precision medicine.

This collaboration builds upon a preexisting partnership between Illumina and Tempus, which has already been focused on addressing unmet testing needs through the development of tools and assays. These tools are intended to span the spectrum from preemptive screening to therapy selection and health economics.

While the press release contains forward-looking statements from both companies, it is noted that these statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations. InvestingPro analysis shows analyst price targets ranging from $75 to $190, reflecting mixed market sentiment. Investors seeking deeper insights into Illumina’s financial health and growth prospects can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks.

The companies have not disclosed specific financial terms or timelines for the collaboration. The announcement is based on a press release statement, and the information presented remains subject to validation by independent sources. Illumina’s stock has experienced significant volatility, with a 49% decline over the past six months, though the company maintains a moderate debt level and healthy current ratio of 1.78.

In other recent news, Illumina has been navigating a series of significant developments. Piper Sandler has maintained its Overweight rating on Illumina, with a price target of $190, following discussions with industry stakeholders about challenges in the next-generation sequencing market. Meanwhile, TD Cowen has adjusted its price target for Illumina to $86, maintaining a Hold rating due to concerns about NIH funding pressures affecting the company’s earnings. Bernstein SocGen Group has reiterated its Market Perform rating and a $130 price target amid changes to Illumina’s board of directors, including the appointment of Keith Meister from Corvex Management. Canaccord Genuity also maintained a Hold rating with a $115 target, expressing a cautious outlook despite acknowledging progress under CEO Jacob Thaysen.

Evercore ISI continues to support Illumina with an Outperform rating and a $160 price target, citing Meister’s board appointment as a positive move. Illumina has been addressing challenges, such as NIH funding reductions and market competition, which have contributed to recent stock performance issues. The company’s efforts to expand into multi-omics and improve market communication are seen as strategic steps forward. Upcoming earnings calls are anticipated to provide further insights into Illumina’s financial performance and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.